SV News
14 March 2024Portfolio NewsCumulus Neuroscience Announces First Patient Enrolled in AccelADx Electroencephalogram (EEG) Study for Early Detection of Alzheimer's Dementia
12 March 2024Portfolio NewsPrilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease
11 March 2024Portfolio NewsNitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference
11 March 2024Portfolio NewsRibometrix to Present New Preclinical Data From RNA-Modulating Small Molecule Programs Targeting eIF4E and c-MYC at the 2024 AACR Annual Meeting- 8 March 2024SV NewsOn International Women's Day SV Venture Partner Ruth McKernan reflects on some achievements of SV biotech portfolio companies
- 4 March 2024Portfolio NewsQurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
- 23 February 2024SV NewsHow Precision Neuroscience and Drug Synergies Could Revolutionize Neurology
- 22 February 2024SV NewsPrecision Neuroscience: A New Frontier in Dementia Research and Beyond
13 February 2024Portfolio NewsBioAge raises $170M as obesity spotlight shifts to oral options, muscle preservers- 13 February 2024Portfolio NewsEyeBio targets registrational trial after early success of Wnt agonist in retinal diseases
13 February 2024Portfolio NewsTransposon Announces Final Results from a Phase 2 Study of its LINE-1 Reverse Transcriptase Inhibitor TPN-101 for the Treatment of Progressive Supranuclear Palsy and Interim Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyo
13 February 2024Portfolio NewsSudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
